These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 3891282)

  • 61. Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae.
    Berry V; Hoover J; Singley C; Woodnutt G
    Antimicrob Agents Chemother; 2005 Mar; 49(3):908-15. PubMed ID: 15728883
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of oral erythromycin ethylsuccinate and clavulanate-potentiated amoxicillin in the treatment of acute respiratory tract infections.
    Shanks N; Macklin J; Coles S
    Clin Ther; 1989; 11(6):812-9. PubMed ID: 2692823
    [TBL] [Abstract][Full Text] [Related]  

  • 63. In vitro activity of aminopenicillins combined with sulbactam, clavulanic acid, or amdinocillin against bacteria isolated from patients with complicated urinary tract infections.
    Naber KG; Wittenberger R
    Rev Infect Dis; 1986; 8 Suppl 5():S604-8. PubMed ID: 3026011
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [In vitro susceptibilities of BRL 25000 (clavulanic acid-amoxicillin) against causative organisms in the field of obstetrics and gynecology].
    Deguchi K; Fukayama S; Nishimura Y; Yokota N; Tanaka S; Yoshihara H; Oda S; Matsumoto Y; Ikegami R; Sato K
    Jpn J Antibiot; 1986 Mar; 39(3):842-52. PubMed ID: 3488425
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Experimental and clinical studies on BRL 25000 (clavulanic acid-amoxicillin) in the field of obstetrics and gynecology].
    Cho N; Fukunaga K; Kunii K
    Jpn J Antibiot; 1983 Mar; 36(3):481-6. PubMed ID: 6876360
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Antibacterial activity and kill kinetics of amoxicillin-clavulanic acid combinations against Escherichia coli and Klebsiella aerogenes.
    Fuglesang JE; Bergan T
    Infection; 1983; 11(6):329-35. PubMed ID: 6365790
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Role of beta-lactamases in the response of pulmonary infections to amoxycillin/clavulanate.
    Stockley RA; Dragicevic P; Burnett D; Hill SL
    J Antimicrob Chemother; 1989 Nov; 24 Suppl B():73-81. PubMed ID: 2606821
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment of respiratory tract infections in children: a study of a combination of amoxycillin and clavulanic acid.
    Fiocchi A; Zuccotti G; Bellù R; Marangione P; Riva E; Giovannini M
    J Int Med Res; 1990; 18(4):326-33. PubMed ID: 2227080
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Synergy of clavulanic acid, sulbactam and tazobactam (YTR 830) with amoxycillin against fifty beta-lactamase-producing strains of Haemophilus influenzae.
    Simonet M; Moittie D; Philippon A; Descamps P; Veron M
    J Antimicrob Chemother; 1989 May; 23(5):798-800. PubMed ID: 2547748
    [No Abstract]   [Full Text] [Related]  

  • 70. [In vitro susceptibilities of causative organisms isolated from patients with primary respiratory tract infections to BRL 25000 (clavulanic acid/amoxicillin)].
    Deguchi K; Fukayama S; Nishimura Y; Yokota N; Tanaka S; Oda S; Matsumoto Y; Ikegami R; Sato K; Fukumoto T
    Jpn J Antibiot; 1985 Oct; 38(10):2797-808. PubMed ID: 3878415
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Respiratory tract infections caused by beta-lactamase producing organisms treated with augmentin.
    Mehtar S
    Scott Med J; 1982; 27 Spec No.():S24-7. PubMed ID: 6984777
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis.
    Nadler JP; Berger J; Nord JA; Cofsky R; Saxena M
    Chest; 1991 Apr; 99(4):1025-6. PubMed ID: 1901260
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Distribution of amoxicillin and clavulanic acid in infected animals and efficacy against experimental infections.
    Boon RJ; Beale AS; Comber KR; Pierce CV; Sutherland R
    Antimicrob Agents Chemother; 1982 Sep; 22(3):369-75. PubMed ID: 7137980
    [TBL] [Abstract][Full Text] [Related]  

  • 74. In-vitro sensitivity of amoxicillin/clavulanic acid (Augmentin) to isolated beta-lactamases and in-vitro antibacterial activity.
    Esposito S; Noviello S
    J Chemother; 1990 Jun; 2(3):167-70. PubMed ID: 2380766
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Beta-lactamase inhibitors. I. In vivo evaluation of an amoxicillin + clavulanic acid combination in the treatment of urinary infections].
    Dalet F; Del Río G
    Rev Clin Esp; 1984 Feb; 172(3):153-7. PubMed ID: 6609385
    [No Abstract]   [Full Text] [Related]  

  • 76. [Progress in chemotherapeutic agents--beta-lactam antibiotics and beta-lactamase inhibitors].
    Uzuka Y; Matsumoto K
    Nihon Rinsho; 1986 Apr; 44(4):824-30. PubMed ID: 3531574
    [No Abstract]   [Full Text] [Related]  

  • 77. A clinical evaluation of clavulanate-potentiated amoxycillin in the management of moderate to severe respiratory tract infections.
    Anyanwu CH; Umeh BU
    J Int Med Res; 1988; 16(3):210-5. PubMed ID: 3044873
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Comparative research on Augmentin].
    Robinson OP
    Antibiot Khimioter; 1992 Sep; 37(9):9-11. PubMed ID: 1444674
    [No Abstract]   [Full Text] [Related]  

  • 79. Cutaneous reactions to amoxicillin-clavulanate among Haitians.
    Paparello SF; Davis CE; Malone JL
    AIDS; 1994 Feb; 8(2):276-7. PubMed ID: 8043237
    [No Abstract]   [Full Text] [Related]  

  • 80. The prevalence of beta-lactamase producing bacteria in subgingival plaque and their sensitivity to Augmentin.
    Legg JA; Wilson M
    Br J Oral Maxillofac Surg; 1990 Jun; 28(3):180-4. PubMed ID: 1983762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.